

Supporting Information © Wiley-VCH 2008

69451 Weinheim, Germany

C-H Functionalization/C-N Bond Formation: Copper-Catalyzed Synthesis of Benzimidazoles from Amidines

Gordon Brasche and Stephen L. Buchwald*

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

Supporting Information

Content

General Considerations	S2
Preparation and Analytical Data of Chemical Compounds	S3
General Procedures for the Synthesis of Amidines from Anilines and Carbonitriles	S3
Analytical Data of the Amidines	S4
General Procedure for the Synthesis of Benzimidazoles from Amidines	S16
Analytical Data of the Benzimidazoles	S16
Reactivity Study of Electron-rich and Electron-poor Amidines	S29
Spectra	S31
References	S37

General Considerations

For the synthesis of amidines, all anilines and carbonitriles were commercially available and used as received, except for 2-(*tert*-butyldimethylsilyl)benzonitrile, which was synthesized from 2-iodobenzonitrile and *tert*-butyldimethylsilylchloride (TBSCl). NaH (dry, 95%) was purchased from Sigma-Aldrich and stored in a nitrogen filled glove box. AlCl₃ (98.5%, extra pure, anhydrous, powder) was obtained from Acros Organics. DMSO (anhydrous, 99.9+%) was purchased from Sigma-Aldrich in a SureSealTM bottle. Cu(OAc)₂ (anhydrous, 99.999%) was obtained from Sigma-Aldrich and stored in a desiccator with Drierite® as drying agent. Similar results were obtained with Cu(OAc)₂ (anhydrous, min. 97%), which was purchased from Strem Chemicals and stored in a desiccator. HOAc (ACS reagent, 99.7+%) was obtained from Sigma-Aldrich. O₂ (extra dry, size 200, minimum purity 99.8%) was obtained from Airgas. *N*-Phenylbenzamidine (97%+) was purchased from Maybridge. All other commercially available materials as solvents and reagents were used as received.

Silica gel chromatography was performed using a Biotage SP4TM EXP Flash Purification System. For the purification of the benzimidazoles, 25+M KP-Sil silica cartridges were used. MeOH or EtOAc was used to transfer the crude reaction material onto the silica gel samplet. The samplet was dried under vacuum prior to usage.

Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury-300 instrument. Chemical shifts (δ) are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (¹H NMR CDCl₃: δ 7.27, DMSO-d₆: δ 2.50; ¹³C NMR CDCl₃: δ 77.23, DMSO- d_6 : δ 39.51) or fluorobenzene (19 F NMR C₆H₅F: δ -113.15) as external standard. ¹³C NMR spectra were recorded with complete proton decoupling. Due to the existence of tautomers, some ¹³C NMR signals could not be detected for most of the NH₂ amidines and NH benzimidazoles. Only distinct signals are reported. Infrared (IR) spectra were recorded on a Perkin Elmer System 2000 FT-IR spectrophotometer. Melting points (mp) were taken on a MEL-TEMP® apparatus and are uncorrected. Gas chromatographic (GC) analyses were performed with a Hewlett-Packard 6890 Series GC System with a capillary column with cross-linked methyl siloxane as the stationary phase (25 m × 0.20 mm). GC conversions and GC yields were calculated using dodecane as internal standard. Analytical high performance liquid chromatography (HPLC) was performed on an Agilent 1100/1200 Series HPLC System with an Agilent Eclipse XDB-C18 $5 \mu m$ stationary phase (150 × 4.6 mm). Microanlyses were carried out by Atlantic Microlab, Inc. (Norcross, GA). In cases where microanalyses were not performed or satisfactory results were not obtained, the ¹H NMR and ¹³C NMR are attached.

Preparation and Analytical Data of Chemical Compounds

2-(tert-Butyldimethylsilyl)benzonitrile. Under a positive N₂ pressure, a dry round bottom flask (200 mL in volume) equipped with a stir bar was charged with 2-iodobenzonitrile (4.58 g, 20.0 mmol) and sealed with a rubber septum. Dry THF (60 mL) was added by syringe, and the solution cooled to -78 °C. tBuLi (29.4 mL, 50.0 mmol, 2.50 equiv, 1.7 M in pentane) was then slowly added by syringe. After addition was complete, the mixture was stirred for 15 min at -78 °C, before a solution of TBSCl (3.92 g, 26.0 mmol, 1.30 equiv) in THF (10 mL) was added by syringe. After a further 20 min at -78 °C, the cooling bath was removed and the reaction mixture was allowed to warm to room temperature. Water (150 mL) and hexanes (50 mL) were consecutively added. The organic layer was separated and the aqueous layer extracted with hexanes (2 \times 100 mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Hex/EtOAc, gradient 0% to 4% EtOAc) to give the title compound as a dark oil, yield 1.96 g (45%, GC: 92% purity). ¹H NMR (300 MHz, CDCl₃) δ 7.67 (dq, J = 7.5, 0.8 Hz, 1H), 7.58 (dq, J = 7.5, 0.8 Hz, 1H), 7.52 (td, J = 7.5, 1.5 Hz, 1H), 7.42 (td, J = 7.5, 1.5 Hz, 1H), 0.91 (s, 9H), 0.44 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 142.44, 136.34, 134.18, 131.31, 129.25, 120.91, 118.14, 26.79, 18.10, -4.78. IR (KBr plate, CDCl₃) v 3058, 2955, 2929, 2858, 2223, 1584, 1470, 1429, 1363, 1260, 1126, 1072, 1008, 938, 840, 824, 764, 726, 685, 653, 589, 558, 472, 406.

General Procedures for the Synthesis of Amidines from Anilines and Carbonitriles

Procedure A. A round bottom flask (100 mL in volume) equipped with a stir bar was charged with NaH (264 mg, 11.0 mmol, 95%, 1.10 equiv) in the glove box. The flask was sealed with a rubber septum and taken out of the glove box. Under a stream of nitrogen, DMSO (5 mL) was added, and the resulting suspension cooled with an ice-water bath prior to the addition of the aniline (12.0 mmol, 1.20 equiv) and the carbonitrile (10.0 mmol). The mixture was kept at 0 °C for 30-60 min and then stirred for the indicated time at room temperature. The septum was removed, and ice-water (50 mL) was added while maintaining vigorous stirring. In the cases, when the amidine precipitated upon

addition of water, the solid was filtered off and dissolved in EtOAc (20 mL). In all other cases, the aqueous layer was extracted with EtOAc (3×20 mL). The extracts were combined and washed with water (2×50 mL). In both of the aforementioned cases, the organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was either purified by silica gel chromatography or recrystallization.

Procedure B. Under an air atmosphere, a pressure flask (75 mL in volume) equipped with a stir bar was charged with the aniline (12.0 mmol, 1.20 equiv) and the carbonitrile (10.0 mmol). AlCl₃ (1.33 g, 10.0 mmol, 1.00 equiv) was added in one portion while stirring the reaction mixture. The flask was tightly sealed with a screw cap and lowered into a preheated oil bath at 120 °C. The reaction mixture was stirred for the indicated time, and taken out of the oil bath. Ice-water (50 mL) was then added to the hot mixture while maintaining vigorous stirring. If necessary, the mixture was warmed with a heat gun to obtain a homogenous aqueous solution, before it was transferred into a separatory funnel. Concentrated aqueous NaOH was added until a pH of 14 was reached, and the aqueous layer was extracted with CHCl₃ (3 × 30 mL). (Caution: Addition of CHCl₃ to base may cause a vigorous reaction. Allow the aqueous layer to cool to room temperature before the extraction with CHCl₃.) The combined organic layers were dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was either purified by silica gel chromatography or recrystallization.

[a] In case of the *tert*-butyl amdines, the aqueous phase was washed with CHCl₃ (3×30 mL) prior to the addition of concentrated aqueous NaOH.

Analytical Data of the Amidines

N-Phenyl-2-methylbenzamidine.^[1] Following representative procedure A, after 15 h reaction time and recrystallization (Hex/EtOAc), white crystals were obtained, yield 1.82 g (87%, mp 127 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.54-7.14 (m, 6H), 7.00 (s, 3H), 4.77 (s, 2H), 2.50 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 130.86, 130.25, 129.36, 127.99, 125.93, 123.01, 121.88, 19.83. IR (KBr plate, CDCl₃) ν 3435, 3288, 3069, 2717, 1637,

1588, 1484, 1456, 1382, 1279, 1245, 1071, 1039, 1023, 907, 842, 780, 768, 729, 697, 658, 520, 507, 459 cm⁻¹. Anal. Calcd. for $C_{14}H_{14}N_2$: C, 79.97; H, 6.71; Found: C, 80.10; H, 6.70.

N-(4-Methoxyphenyl)-2-methylbenzamidine. Following representative procedure A, after 15 h reaction time and recrystallization (Hex/EtOAc), a gray powder was obtained, yield 1.84 g (77%, mp 116 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.43 (s, 1H), 7.35-7.12 (m, 3H), 7.08-6.52 (m, 4H), 4.78 (s, 2H), 3.78 (s, 3H), 2.49 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 130.82, 129.29, 127.99, 125.92, 122.81, 114.73, 55.59, 19.82. IR (KBr plate, CDCl₃) v 3437, 3287, 3062, 2954, 2834, 1639, 1503, 1455, 1441, 1376, 1286, 1240, 1180, 1103, 1035, 858, 833, 821, 784, 765, 738, 531, 465 cm⁻¹. Anal. Calcd. for C₁₅H₁₆N₂O: C, 74.97; H, 6.71; Found: C, 75.10; H, 6.71.

N-(**4-Fluorophenyl**)-**2-methylbenzamidine.** Following representative procedure A, after 15 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a brownish solid was obtained, yield 1.86 g (81%, mp 92 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.58-7.14 (m, 4H), 7.12-6.62 (m, 4H), 4.91 (s, 2H), 2.47 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 130.86, 129.44, 128.01, 125.96, 123.00, 116.18, 19.81. 19 F NMR (282 MHz, CDCl₃) δ -121.19 (s). IR (KBr plate, CDCl₃) ν 3435, 3287, 3104, 1625, 1592, 1497, 1444, 1384, 1212, 1149, 1090, 864, 845, 821, 793, 769, 752, 705, 521, 478 cm⁻¹. Anal. Calcd. for C₁₄H₁₃FN₂: C, 73.66; H, 5.74; Found: C, 73.65; H, 5.68.

N-(4-Chlorophenyl)-2-methylbenzamidine. Following representative procedure A, after 15 h reaction time and recrystallization (Hex/EtOAc), an off-white solid was obtained, yield 2.04 g (83%, mp 119 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.64-7.04 (m, 6H), 6.90 (s, 2H), 4.79 (s, 2H), 2.47 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 130.90, 129.52, 127.98, 125.98, 123.34, 19.82. IR (KBr plate, CDCl₃) v 3433, 3285, 3064, 2718, 1623, 1599, 1585, 1484, 1444, 1385, 1245, 1168, 1098, 1043, 10101, 861, 815, 770, 730, 678, 513, 460 cm⁻¹. Anal. Calcd. for C₁₄H₁₃ClN₂: C, 68.71; H, 5.35; Found: C, 68.73; H, 5.32.

N-(**4-Bromophenyl**)-**2-methylbenzamidine.** Following representative procedure A, after 15 h reaction time and recrystallization (Hex/EtOAc), gray crystals were obtained, yield 2.08 g (72%, mp 135 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.64-7.08 (m, 6H), 6.84 (s, 2H), 4.75 (s, 2H), 2.47 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 130.93, 129.57, 128.00, 126.00, 123.80, 19.85. IR (KBr plate, CDCl₃) ν 3444, 3288, 3063, 1635, 1580, 1481, 1455, 1377, 1243, 1098, 1070, 1007, 859, 831, 809, 768, 731, 664, 511 cm⁻¹. Anal. Calcd. for C₁₄H₁₃BrN₂: C, 58.15; H, 4.53; Found: C, 57.92; H, 4.50.

N-Phenyl-2-(trifluoromethyl)benzamidine DMSO adduct. Following representative procedure A, after 16 h reaction time and recrystallization (Hex/EtOAc), orange crystals were obtained, yield 2.99 g (87%, mp 96-99 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.13 (d, J = 7.8 Hz, 1H), 7.70-7.47 (m, 3H), 7.42-7.26 (m, 2H), 7.12-6.92 (m, 3H), 2.57 (s, 6H). 13 C NMR (75 MHz, CDCl₃) δ 132.13, 130.25, 130.11, 129.61, 129.54, 128.25, 127.84, 126.67, 126.60, 126.53, 126.47, 123.37, 121.53, 41.07. 19 F NMR (282 MHz, CDCl₃) δ - 58.32 (s). IR (KBr plate, CDCl₃) ν 3303, 1643, 1592, 1486, 1448, 1377, 1316, 1271,

1239, 1175, 1131, 1052, 1035, 953, 909, 837, 774, 700, 669, 646, 599, 524 cm⁻¹. Anal. Calcd. for C₁₆H₁₇F₃N₂OS: C, 56.13; H, 5.00; Found: C, 56.26; H, 4.96.

N-(4-Methoxyphenyl)-2-(trifluoromethyl)benzamidine. Following representative procedure A, after 15 h reaction time and recrystallization (Hex/EtOAc), brown needles were obtained, yield 2.50 g (85%, mp 130-131 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.72 (d, J = 7.5 Hz, 1H), 7.70-7.48 (m, 3H), 7.06-6.78 (m, 4H), 4.89 (s, 2H), 3.79 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 155.89, 132.17, 130.16, 129.54, 126.70, 126.63, 126.56, 126.50, 122.53, 114.95, 55.63. ¹⁹F NMR (282 MHz, CDCl₃) δ -58.36 (s). IR (KBr plate, CDCl₃) v 3291, 3069, 2837, 1643, 1504, 1467, 1379, 1316, 1289, 1272, 1239, 1173, 1130, 1052, 1035, 860, 809, 769, 742, 712, 661, 598, 534 cm⁻¹. Anal. Calcd. for C₁₅H₁₃F₃N₂O: C, 61.22; H, 4.45; Found: C, 61.31; H, 4.27.

N-(3-Methoxyphenyl)-2-(trifluoromethyl)benzamidine. Following representative procedure A, after 15 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a red solid was obtained, yield 2.63 g (89%, mp 80-82 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.72 (d, J = 7.8 Hz, 1H), 7.70-7.48 (m, 3H), 7.24 (t, J = 7.8 Hz, 1H), 6.72-6.48 (m, 3H), 4.91 (m, 2H), 3.80 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 132.18, 130.40, 130.12, 129.64, 128.28, 127.86, 126.71, 126.65, 126.58, 126.52, 113.78, 109.17, 107.16, 55.36. ¹⁹F NMR (282 MHz, CDCl₃) δ -58.31 (s). IR (KBr plate, CDCl₃) v 3453, 3291, 3071, 2837, 1644, 1594, 1485, 1451, 1435, 1377, 1316, 1283, 1199, 1174, 1130, 1052, 1036, 928, 860, 771, 697, 675, 648, 599, 459 cm⁻¹. Anal. Calcd. for C₁₅H₁₃F₃N₂O: C, 61.22; H, 4.45; Found: C, 61.06; H, 4.33.

N-(4-*tert*-Butoxycarbonylphenyl)-2-(trifluoromethyl)benzamidine. Following representative procedure A, after 15 h reaction time and recrystallization (Hex/EtOAc), light yellow crystals were obtained, yield 3.02 g (83%, mp 181-182 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.94 (s, 2H), 7.76-7.42 (m, 4H), 6.98 (s, 2H), 4.86 (s, 2H), 1.56 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 165.93, 132.23, 131.41, 130.05, 129.82, 126.74, 126.68, 121.27, 80.82, 28.41. ¹⁹F NMR (282 MHz, CDCl₃) δ -58.65 (s). IR (KBr plate, CDCl₃) ν 3407, 3192, 2978, 1704, 1648, 1597, 1501, 1368, 1315, 1254, 1162, 1122, 1052, 1035, 871, 852, 768, 707, 650 cm⁻¹. Anal. Calcd. for C₁₉H₁₉F₃N₂O₂: C, 62.63; H, 5.26; Found: C, 62.78; H, 5.21.

N-(3-*tert*-Butoxycarbonylphenyl)-2-(trifluoromethyl)benzamidine. Following representative procedure A, after 15 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 60% EtOAc), a glassy solid was obtained, yield 2.20 g (60%, no mp). ¹H NMR (300 MHz, CDCl₃) δ 7.84-7.47 (m, 6H), 7.46-7.32 (m, 1H), 7.22-7.08 (m, 1H), 4.89 (s, 2H), 1.59 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 165.91, 132.18, 130.09, 129.71, 128.30, 127.88, 126.74, 126.67, 126.61, 126.54, 125.95, 124.48, 122.44, 81.17, 28.32. ¹⁹F NMR (282 MHz, CDCl₃) δ -58.28 (s). IR (KBr plate, CDCl₃) ν 3457, 3353, 3070, 2980, 2934, 1711, 1644, 1594, 1478, 1451, 1431, 1370, 1316, 1273, 1258, 1230, 1173, 1132, 1078, 1052, 1035, 933, 918, 850, 833, 769, 751, 734, 701, 677, 646, 599 cm⁻¹. Anal. Calcd. for C₁₉H₁₉F₃N₂O₂: C, 62.63; H, 5.26; Found: C, 62.43; H, 5.16.

N-(**4-Iodophenyl**)-**2**-(**trifluoromethyl**)**benzamidine.** Following representative procedure A, after 16 h reaction time and recrystallization (Hex/EtOAc), gray needles were obtained, yield 3.20 g (82%, mp 139 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.73 (d, J = 7.8 Hz, 1H), 7.70-7.49 (m, 5H), 6.76 (s, 2H), 4.84 (s, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 138.63, 132.24, 130.05, 129.83, 126.82, 126.75, 126.69, 126.62, 123.93, 86.92. ¹⁹F NMR (282 MHz, CDCl₃) δ -58.34 (s). IR (KBr plate, CDCl₃) ν 3442, 3288, 3065, 1646, 1604, 1576, 1479, 1451, 1383, 1315, 1270, 1241, 1175, 1125, 1051, 1034, 1004, 864, 804, 768, 711, 670, 647, 602, 510 cm⁻¹. Anal. Calcd. for C₁₄H₁₀F₃IN₂: C, 43.10; H, 2.58; Found: C, 43.16; H, 2.53.

N-Phenyl-2-methoxybenzamidine. Following representative procedure A, after 17 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a red oil was obtained, which crystallized after a while at room temperature to give a red solid, yield 2.12 g (94%, mp 71-78 °C). 1 H NMR (300 MHz, CDCl₃) δ 8.28-8.15 (m, 1H), 7.48-7.28 (m, 3H), 7.14-6.92 (m, 5H), 5.59 (s, 2H), 3.92 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 131.65, 131.41, 129.64, 123.78, 122.83, 122.04, 111.65, 55.99. IR (KBr plate, CDCl₃) v 3488, 3381, 3074, 2838, 1626, 1587, 1489, 1464, 1437, 1367, 1275, 1240, 1182, 1163, 1100, 1047, 1023, 906, 823, 753, 699, 648, 517 cm⁻¹. Anal. Calcd. for $C_{14}H_{14}N_2O$: C, 74.31; H, 6.24; Found: C, 74.08; H, 6.16.

N-(4-Chlorophenyl)-2-methoxybenzamidine. Following representative procedure A, after 14 h reaction time and recrystallization (Hex/EtOAc), red crystals were obtained, yield 2.22 g (85%, mp 94 °C). 1 H NMR (300 MHz, CDCl₃) δ 8.12 (s, 1H), 7.42 (td, J =

7.5, 1.8 Hz, 1H), 7.28 (d, J = 8.4 Hz, 2H), 7.06 (t, J = 7.5 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 8.4 Hz, 2H), 5.57 (s, 2H), 3.90 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 131.85, 131.23, 129.59, 127.88, 123.47, 123.32, 121.41, 111.65, 55.97. IR (KBr plate, CDCl₃) ν 3490, 3383, 3078, 2940, 2838, 1627, 1484, 1464, 1437, 1369, 1301, 1275, 1241, 1181, 1164, 1091, 1047, 1024, 1010, 859, 832, 804, 753, 675, 514 cm⁻¹. Anal. Calcd. for C₁₄H₁₄ClN₂O: C, 64.49; H, 5.03; Found: C, 64.33; H, 4.98.

N-Phenyl-2-chlorobenzamidine. Following representative procedure A, after 14 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a yellow solid was obtained, yield 2.20 g (95%, mp 104-105 °C). H NMR (300 MHz, CDCl₃) δ 7.71 (s, 1H), 7.52-6.78 (m, 8H), 4.94 (s, 2H). NMR (75 MHz, CDCl₃) δ 130.75, 130.22, 129.75, 127.22, 123.43, 122.05, 121.72. IR (KBr plate, CDCl₃) ν 3449, 3290, 3074, 1639, 1590, 1486, 1434, 1375, 1237, 1070, 1049, 1033, 907, 837, 763, 699, 648, 505 cm⁻¹. Anal. Calcd. for C₁₃H₁₁ClN₂: C, 67.68; H, 4.81; Found: C, 67.76; H, 4.94.

N-Phenyl-2-(*tert*-butyldimethylsilyl)benzamidine. Due to the instability of the amidine containing the TBS group, a modified procedure A was used.

A round bottom flask (100 mL in volume) equipped with a stir bar was charged with NaH (119 mg, 4.95 mmol, 95%, 1.10 equiv) in the glove box. The flask was sealed with a rubber septum and taken out of the glove box. Under a stream of nitrogen, DMSO (5 mL) was added, and the suspension cooled to 0 °C using an immersion cooler. Aniline (492 μL, 5.40 mmol, 1.20 equiv) and 2-(*tert*-butyldimethylsilyl)benzonitrile (978 mg, 4.50 mmol) were added, and the mixture was stirred at 0 °C for 48 h. The septum was removed, and water (50 mL) was added, followed by extraction of the aqueous layer with EtOAc (3 × 30 mL). The combined extracts were washed with water (2 × 30 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc) to give the

amidine as a brown solid, yield 192 mg (14%, mp 108-112 °C) and 496 mg of reisolated 2-(*tert*-butyldimethylsilyl)benzonitrile. ¹H NMR (300 MHz, CDCl₃) δ 7.69-7.58 (m, 1H), 7.57-7.29 (m, 5H), 7.24-6.98 (m, 3H), 4.96 (bs, 2H), 0.98 (s, 9H), 0.40 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 136.91, 129.58, 129.03, 128.49, 127.90, 123.18, 121.60, 27.54, 17.99, -3.28. IR (KBr plate, CDCl₃) ν 3434, 3285, 3054, 2952, 2930, 2857, 1621, 1585, 1558, 1482, 1431, 1380, 1254, 1119, 1072, 906, 837, 826, 813, 774, 735, 701, 670, 525, 511, 469, 417 cm⁻¹.

N-Phenyl-4-chloro-2-methylbenzamidine. Following representative procedure A, after 14 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), an off-white solid was obtained, yield 0.82 g (34%, mp 104-105 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.46-7.14 (m, 5H), 7.10-6.84 (m, 3H), 4.88 (s, 2H), 2.45 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 135.04, 130.79, 129.42, 126.12, 123.27, 121.79, 19.78. IR (KBr plate, CDCl₃) v 3437, 3284, 3077, 1636, 1587, 1484, 1448, 1406, 1371, 1237, 1200, 1112, 909, 882, 815, 743, 699, 596, 516 cm⁻¹. Anal. Calcd. for C₁₄H₁₃ClN₂: C, 68.71; H, 5.35; Found: C, 68.57; H, 5.36.

N-(4-Bromophenyl)-4-chloro-2-methylbenzamidine. Following representative procedure A, after 17 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), an off-white solid was obtained, yield 1.76 g (54%, mp 129 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.62-7.06 (m, 5H), 6.80 (s, 2H), 4.91 (s, 2H), 2.44 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 135.23, 132.53, 130.83, 129.34, 126.17, 123.68, 19.76. IR (KBr plate, CDCl₃) ν 3432, 3291, 2983, 1639, 1579, 1480, 1446, 1401, 1374, 1242, 1202, 1171, 1111, 1068, 1007, 883, 861, 841, 828, 771, 735, 687, 632, 577, 519 cm⁻¹. Anal. Calcd. for C₁₄H₁₂BrClN₂: C, 51.96; H, 3.74; Found: C, 52.19; H, 3.70.

N-Phenyl-5-fluoro-2-methylbenzamidine. Following representative procedure A, after 14 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a yellow solid was obtained, yield 2.12 g (93%, mp 92 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.48-6.82 (m, 8H), 4.81 (s, 2H), 2.45 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 162.54, 132.43, 132.33, 129.58, 123.26, 121.77, 116.35, 116.08, 115.14, 114.84, 19.08. ¹⁹F NMR (282 MHz, CDCl₃) δ -117.24 (s). IR (KBr plate, CDCl₃) v 3447, 3287, 3076, 1591, 1498, 1432, 1361, 1266, 1222, 1185, 1070, 1025, 998, 929, 906, 877, 836, 816, 770, 735, 698, 514, 458 cm⁻¹. Anal. Calcd. for C₁₄H₁₃FN₂: C, 73.66; H, 5.74; Found: C, 73.53; H, 5.68.

N-(3-Bromo-4-methylphenyl)-2-(trifluoromethyl)benzamidine. Following representative procedure A, after 15 h reaction time and recrystallization (Hex/EtOAc), orange needles were obtained, yield 3.12 g (87%, mp 139 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.72 (d, J = 7.5 Hz, 1H), 7.69-7.48 (m, 3H), 7.18 (s, 2H), 6.93-6.76 (m, 1H), 4.90 (s, 2H), 2.36 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 132.20, 131.69, 130.04, 129.74, 128.27, 127.85, 126.76, 126.70, 126.63, 126.56, 125.10, 120.72, 22.42. 19 F NMR (282 MHz, CDCl₃) δ -58.34 (s). IR (KBr plate, CDCl₃) v 3485, 3146, 1614, 1597, 1579, 1484, 1367, 1316, 1271, 1234, 1182, 1133, 1111, 1053, 1034, 960, 891, 879, 827, 771, 698, 641, 600, 576, 485, 406, 438 cm⁻¹. Anal. Calcd. for C₁₅H₁₂BrF₃N₂: C, 50.44; H, 3.39; Found: C, 50.47; H, 3.34.

N-Methyl,*N*-phenyl-2-methylbenzamidine. Following representative procedure B, after 30 min reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a red oil was obtained, yield 1.66 g (74%). ¹H NMR (300 MHz, CDCl₃) δ 7.22-6.98 (m, 9H), 6.70-5.80 (bs, 1H), 3.47 (s, 3H), 2.25 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 168.09, 145.71, 138.73, 134.08, 130.26, 128.72, 128.51, 128.15, 126.49, 125.65, 125.42, 39.05, 19.64. IR (KBr plate) ν 3314, 3062, 2954, 1576, 1496, 1441, 1386, 1321, 1285, 1173, 1115, 1028, 1006, 990, 945, 906, 859, 813, 773, 732, 699, 643, 588, 547, 532, 465 cm⁻¹.

N-Methyl,*N*-phenyl-2-chlorobenzamidine. Following representative procedure B, after 20 min reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a purple solid was obtained, yield 1.99 g (81%, mp 75-76 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.23-6.98 (m, 9H), 6.06 (bs, 1H), 3.45 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 165.05, 145.41, 137.73, 131.03, 129.69, 129.65, 129.57, 128.80, 126.67, 126.57, 125.81, 38.91. IR (KBr plate, CDCl₃) v 3659, 3319, 3059, 2939, 2902, 1950, 1587, 1496, 1436, 1388, 1321, 1262, 1180, 1106, 1056, 1034, 991, 948, 909, 856, 764, 739, 700, 637, 585, 537, 469, 435, 416 cm⁻¹. Anal. Calcd. for C₁₄H₁₃ClN₂: C, 68.71; H, 5.35; Found: C, 68.76; H, 5.33.

N-(**4-Bromophenyl**), *N*-methyl-**2-chlorobenzamidine.** Following representative procedure B, after 30 min reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a brownish solid was obtained, yield 2.63 g (81%, mp 88 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.29-7.08 (m, 6H), 6.95 (dt, J = 8.7, 2.1 Hz, 2H), 6.74-6.10

(bs, 1H), 3.42 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 164.93, 144.61, 137.46, 131.94, 131.00, 130.03, 129.94, 129.56, 128.23, 126.87, 119.11, 38.93. IR (KBr plate, CDCl₃) ν 3318, 3058, 1601, 1580, 1491, 1438, 1383, 1322, 1263, 1180, 1104, 1055, 1034, 1010, 995, 855, 831, 766, 743, 714, 695, 644, 584, 538, 440 cm⁻¹. Anal. Calcd. for $C_{14}H_{13}BrClN_2$: C, 51.96; H, 3.74; Found: C, 51.91; H, 3.65.

N-(3-Bromophenyl),*N*-methyl-2-chlorobenzamidine. Following representative procedure B, after 30 min reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a gray oil was obtained, yield 2.75 g (85%). ¹H NMR (300 MHz, CDCl₃) δ 7.30-7.11 (m, 6H), 7.05-6.97 (m, 2H), 6.84-5.92 (bs, 1H), 3.44 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 164.92, 146.77, 137.32, 131.05, 130.09, 130.00, 129.92, 129.60, 129.53, 128.77, 126.88, 125.25, 122.10, 38.92. IR (KBr plate) v 3659, 3317, 3060, 2959, 1929, 1599, 1435, 1322, 1263, 1181, 1110, 1056, 1037, 1000, 948, 869, 768, 696, 658, 636, 601, 469, 444, 417 cm⁻¹. Anal. Calcd. for C₁₄H₁₃BrClN₂: C, 51.96; H, 3.74; Found: C, 51.93; H, 3.78.

N-Phenyl-*tert*-butylamidine. Following representative procedure B, except that the scale was 20 mmol instead of 10 mmol and the reaction temperature was 140 °C, after 40 min reaction time and recrystallization (Hex), gray needles were obtained, yield 1.98 g (56%, mp 102 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.34-7.26 (m, 2H), 7.03-6.97 (m, 1H), 6.88-6.81 (m, 2H), 4.39 (s, 2H), 1.30 (s, 9H). 13 C NMR (75 MHz, CDCl₃) δ 164.44, 150.30, 129.58, 122.68, 121.79, 36.94, 28.70. IR (KBr plate, CDCl₃) v 3500, 3396, 2958, 1630, 1589, 1477, 1398, 1346, 1253, 1217, 1069, 912, 830, 774, 727, 697, 535, 495 cm⁻¹. Anal. Calcd. for C₁₁H₁₆N₂: C, 74.96; H, 9.15; Found: C, 74.83; H, 9.14.

N-(4-Methylphenyl)-*tert*-butylamidine. Following representative procedure B, except that the scale was 20 mmol instead of 10 mmol and the reaction temperature was 140 °C, after 40 min reaction time and recrystallization (Hex), yellow crystals were obtained, yield 2.24 g (59%, mp 106-107 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.13-7.07 (m, 2H), 6.72 (dt, J = 8.1, 2.1 Hz, 2H), 4.40 (s, 2H), 2.30 (s, 3H), 1.29 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 164.58, 147.48, 131.87, 130.14, 121.60, 36.92, 28.71, 20.99. IR (KBr plate, CDCl₃) ν 3500, 3387, 2961, 1591, 1505, 1478, 1396, 1347, 1256, 1219, 1105, 909, 872, 851, 815, 767, 734, 524, 497 cm⁻¹. Anal. Calcd. for C₁₂H₁₈N₂: C, 75.74; H, 9.53; Found: C, 75.85; H, 9.54.

N-(4-Methoxyphenyl)-*tert*-butylamidine. Following representative procedure A, after 15 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a red solid was obtained, yield 0.77 g (37%, mp 103-104 °C). ¹H NMR (300 MHz, CDCl₃) δ 6.85 (dt, J = 9.0, 2.7 Hz, 2H), 6.75 (dt, J = 9.0, 2.7 Hz, 2H), 4.40 (s, 2H), 3.77 (s, 3H), 1.28 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 164.99, 155.38, 143.21, 122.63, 114.86, 55.59, 36.92, 28.71. IR (KBr plate, CDCl₃) v 3464, 3423, 3321, 2965, 2833, 1598, 1503, 1482, 1464, 1400, 1353, 1287, 1238, 1182, 1163, 1100, 1070, 1037, 909, 878, 857, 818, 777, 735, 712, 522, 464 cm⁻¹. Anal. Calcd. for C₁₂H₁₉N₂O: C, 69.87; H, 8.80; Found: C, 69.73; H, 8.81.

N-(**4-Bromophenyl**)-*tert*-butylamidine. Following representative procedure B, except that the scale was 20 mmol instead of 10 mmol and the reaction temperature was 140 °C, after 40 min reaction time and recrystallization (Hex), white needles were obtained, yield 2.86 g (56%, mp 123 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.39 (dt, J = 8.7, 2.4 Hz, 2H), 6.71 (dt, J = 8.7, 2.4 Hz, 2H), 4.39 (s, 2H), 1.28 (s, 9H). 13 C NMR (75 MHz, CDCl₃) δ

164.83, 149.47, 132.56, 123.70, 115.42, 37.01, 28.65. IR (KBr plate, CDCl₃) v 3501, 3381, 2960, 1647, 1621, 1595, 1475, 1395, 1365, 1345, 1256, 1215, 1093, 1068, 1005, 871, 848, 804, 644, 543, 504, 466 cm⁻¹. Anal. Calcd. for C₁₁H₁₅BrN₂: C, 51.78; H, 5.93; Found: C, 51.77; H, 5.92.

General Procedure for the Synthesis of Benzimidazoles from Amidines

An oven-dried disposable test tube (15 mL in volume) equipped with a stir bar and a rubber septum was cooled to room temperature under vacuum and backfilled with O₂. With the tube open to the air, the amidine (1.00 mmol) and Cu(OAc)₂ (27.2 mg, 0.15 mmol, 15 mol%) were added. The tube was evacuated and backfilled with O2, followed by addition of DMSO (2 mL) by syringe. The reaction mixture was degassed by sonication under vacuum and backfilled with O₂ (this procedure was carried out three times). An O₂-filled balloon was attached to a needle with the aid of a small piece of rubber tubing. The needle was inserted through the rubber septum, and HOAc (286 µL, 5.00 mmol, 5.00 equiv) was added by syringe. The reaction mixture was lowered into a preheated oil bath at 100 °C and stirred for the indicated time. After allowing the reaction mixture to cool to room temperature, the septum was removed and ethyl acetate (8 mL), distilled water (4 mL), and aqueous 30% NH₄OH (4 mL) were added. The aqueous layer was extracted with ethyl acetate (2×8 mL). In a round bottom flask (50 mL in volume) equipped with a stir bar, the combined organic layers were stirred with activated charcoal (5-20 mg, NORIT CN1, decolorizing from Acros Organics) for 10-15 min, before being dried over MgSO₄, filtered through Celite, and concentrated under reduced pressure. The residue was purified by silica gel chromatography.

Analytical Data of the Benzimidazoles

2-Phenylbenzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 60% EtOAc), a brownish solid was obtained, yield 123 mg (63%, mp 286-289 °C). ¹H NMR (300 MHz, DMSO-

 d_6) δ 12.94 (s, 1H), 8.23-8.15 (m, 2H), 7.76-7.44 (m, 5H), 7.26-7.16 (m, 2H). The 1 H NMR is identical to a sample of 2-phenylbenzimidazole purchased from Acros Organics.

2-(2-Methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 60% EtOAc), a white solid was obtained, yield 185 mg (89%, mp 223-224 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.67 (s, 1H), 7.79-7.72 (m, 1H), 7.72-7.44 (m, 2H), 7.43-7.31 (m, 3H), 7.26-7.16 (m, 2H), 2.62 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 151.99, 137.05, 131.30, 130.11, 129.48, 129.34, 125.99, 21.11. IR (KBr pellet) v 2872, 1592, 1542, 1449, 1407, 1370, 1315, 1275, 1229, 1099, 972, 765, 742, 726, 454 cm⁻¹. Anal. Calcd. for $C_{14}H_{12}N_2$: C, 80.74; H, 5.81; Found: C, 80.68; H, 5.81.

5-Methoxy-2-(2-methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 60% EtOAc), an orange solid was obtained, yield 166 mg (70%, mp 135 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.49 (s, 1H), 7.77-6.78 (m, 7H), 3.80 (s, 3H), 2.61 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 136.85, 131.31, 130.19, 129.26, 129.10, 125.98, 55.46, 21.19. IR (KBr pellet) ν 2959, 1630, 1592, 1542, 1459, 1404, 1322, 1267, 1199, 1158, 1115, 1095, 1029, 972, 826, 771, 728, 671, 629, 569, 454 cm⁻¹. Anal. Calcd. for C₁₄H₁₅N₂O: C, 75.61; H, 5.92; Found: C, 75.37; H, 5.93.

5-Fluoro-2-(2-methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 80% EtOAc), a white powder was obtained, yield 194 mg (86%, mp 198 °C). 1 H NMR (300 MHz, DMSO- d_6) δ 12.78 (s, 1H), 7.78-7.28 (m, 6H), 7.14-7.00 (m, 1H), 2.60 (s, 3H). 13 C NMR (75 MHz, DMSO- d_6) δ 137.06, 131.35, 129.78, 129.51, 129.45, 126.04, 21.08. 19 F NMR (282 MHz, DMSO- d_6) δ -119.21 (s), -121.11 (s). IR (KBr pellet) v 2667, 1631, 1602, 1491, 1448, 1410, 1363, 1309, 1258, 1220, 1144, 1112, 963, 842, 801, 744, 759, 731, 614, 569, 495, 454, 431 cm⁻¹. Anal. Calcd. for C₁₄H₁₁FN₂: C, 74.32; H, 4.90; Found: C, 74.02; H, 4.93.

5-Chloro-2-(2-methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 80% EtOAc), a white powder was obtained, yield 216 mg (89%, mp 178 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.85 (s, 1H), 7.80-7.33 (m, 6H), 7.23 (d, J = 8.4 Hz, 1H), 2.60 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 137.16, 131.38, 129.66, 129.59, 129.52, 126.06, 21.06. IR (KBr pellet) v 2963, 1618, 1584, 1543, 1441, 1397, 1304, 1275, 1223, 1096, 1059, 969, 925, 856, 804, 770, 731, 600, 455 cm⁻¹. Anal. Calcd. for C₁₄H₁₁ClN₂: C, 69.28; H, 4.57; Found: C, 69.21; H, 4.57.

5-Bromo-2-(2-methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), an off-white solid was obtained, yield 256 mg (89%, mp 184-185 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.85 (s, 1H), 7.80 (s, 1H), 7.78-7.72 (m, 1H), 7.57 (d, J = 8.4

Hz, 1H), 7.45-7.32 (m, 4H), 2.60 (s, 3H). 13 C NMR (75 MHz, DMSO- d_6) δ 153.21, 137.17, 131.37, 129.66, 129.54, 129.53, 126.05, 124.79, 114.07, 21.06. IR (KBr pellet) v 2698, 1581, 1543, 1487, 1438, 1394, 1305, 1275, 1223, 1097, 1045, 971, 915, 854, 806, 768, 754, 731, 681, 593, 569485, 454, 418 cm⁻¹. Anal. Calcd. for $C_{14}H_{11}BrN_2$: C, 58.56; H, 3.86; Found: C, 58.49; H, 3.82.

$$F_3C$$

2-(2-(Trifluoromethyl)phenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 80% EtOAc), an off-white solid was obtained, yield 227 mg (87%, mp 270-273 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.81 (s, 1H), 7.98-7.90 (m, 1H), 7.89-7.72 (m, 3H), 7.63 (s, 2H), 7.29-7.20 (m, 2H). ¹³C NMR (75 MHz, DMSO- d_6) δ 149.44, 132.45, 132.25, 130.35, 130.33, 130.30, 130.27, 130.24, 128.49, 128.08, 127.67, 127.27, 126.75, 126.68, 126.61, 126.54, 125.59, 121.96. ¹⁹F NMR (282 MHz, DMSO- d_6) δ -56.43 (s). IR (KBr pellet) v 3047, 2788, 1591, 1544, 1493, 1479, 1456, 1441, 1407, 1374, 1311, 1281, 1269, 1223, 1182, 1121, 1057, 1035, 1007, 972, 766, 751, 692, 647, 597, 567, 430, 421 cm⁻¹. Anal. Calcd. for C₁₄H₉F₃N₂: C, 64.12; H, 3.46; Found: C, 64.21; H, 3.45.

5-Methoxy-2-(2-(trifluoromethyl)phenyl)benzimidazole. Following the representative procedure using the *para* substituted amidine, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 70% EtOAc), a light orange foam was obtained, yield 213 mg (73%, mp 168 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.64 (s, 1H), 7.93 (d, J = 7.5 Hz, 1H), 7.87-7.70 (m, 3H), 7.60-7.44 (m, 1H), 7.10 (s, 1H), 6.87 (dd, J = 8.7, 2.4 Hz, 1H), 3.81 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 132.41, 132.19, 130.44, 130.41, 130.05, 127.97, 127.57, 126.75, 126.68, 126.61, 126.54, 125.54, 121.99, 55.47. ¹⁹F NMR (282 MHz, DMSO- d_6) δ -56.45 (s). IR (KBr pellet) ν 2932, 1634, 1594, 1405,

1359, 1315, 1268, 1121, 1056, 1034, 974, 835, 814, 773, 694, 648, 597, 563, 435 cm⁻¹. Anal. Calcd. for C₁₅H₁₁F₃N₂O: C, 61.64; H, 3.79; Found: C, 61.73; H, 3.84.

The reaction was also conducted with the *meta* substituted amidine to give 5-methoxy-2-(2-(trifluoromethyl)phenyl)benzimidazole as the main product. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 70% EtOAc), a light yellow foam was obtained, yield 216 mg (74%, mp 161 °C; GC: 19:1 mixture of regioisomers in favor of the isomer shown above; the yield corresponds to the mixture of compounds).

$$_{\text{fBuO}_2\text{C}}$$
 $\stackrel{\text{H}}{\underset{\text{N}}{\bigvee}}$ $\stackrel{\text{H}}{\underset{\text{F}_3\text{C}}{\bigvee}}$

5-*tert*-**Butoxycarbonyl-2-(2-(trifluoromethyl)phenyl)benzimidazole.** Following the representative procedure using the *para* substituted amidine, after 36 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), a white foam was obtained, yield 318 mg (88%, no mp). 1 H NMR (300 MHz, DMSO- d_6) δ 13.13 (s, 1H), 8.20 (s, 1H), 7.96 (d, J = 7.5 Hz, 1H), 7.91-7.75 (m, 4H), 7.69 (d, J = 8.7 Hz, 1H), 1.57 (s, 9H). 13 C NMR (75 MHz, DMSO- d_6) δ 165.46, 151.83, 132.56, 132.20, 130.62, 129.67, 129.65, 128.52, 128.11, 127.71, 127.30, 126.86, 126.79, 126.72, 126.66, 125.52, 125.40, 123.33, 121.89, 80.35, 27.91. 19 F NMR (282 MHz, DMSO- d_6) δ -56.52 (s). IR (KBr pellet) v 2979, 1710, 1626, 1585, 1549, 1478, 1445, 1408, 1370, 1315, 1167, 1055, 1036, 951, 845, 771, 695, 647, 598, 565, 426 cm⁻¹. Anal. Calcd. for C₁₉H₁₇F₃N₂O₂: C, 62.98; H, 4.73; Found: C, 62.74; H, 4.90.

The reaction was also conducted with the *meta* substituted amidine to give 5-*tert*-butoxy-carbonyl-2-(2-(trifluoromethyl)phenyl)benzimidazole as product. After 36 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 60% EtOAc), a white foam was obtained, yield 251 mg (69%, no mp; GC: 90% conversion of the starting material; no regioisomer detected by GC and HPLC).

5-Iodo-2-(2-(trifluoromethyl)phenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), a white solid was obtained, yield 345 mg (89%, mp 191-193 °C). 1 H NMR (300 MHz, DMSO- d_6) δ 12.99 (s, 1H), 7.99 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.89-7.74 (m, 3H), 7.54 (dd, J = 8.4 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H). 13 C NMR (75 MHz, DMSO- d_6) δ 150.20, 132.48, 132.23, 130.68, 130.48, 129.71, 129.68, 129.65, 129.62, 128.48, 128.08, 127.67, 127.26, 126.79, 126.72, 126.65, 126.58, 125.50, 121.87. 19 F NMR (282 MHz, DMSO- d_6) δ -56.49 (s). IR (KBr pellet) v 2783, 1608, 1582, 1547, 1488, 1449, 1429, 1314, 1268, 1215, 1178, 1133, 1057, 1034, 972, 907, 808, 770, 693, 669, 647, 596, 562, 421 cm⁻¹. Anal. Calcd. for C₁₄H₁₉F₃IN₂: C, 43.32; H, 2.08; Found: C, 43.33; H, 2.05.

2-(2-Methoxyphenyl)benzimidazole.^[2] Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 70% EtOAc), an off-white solid was obtained, yield 153 mg (68%, mp 175-178 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.16 (s, 1H), 8.36 (dd, J = 7.8, 1.8 Hz, 1H), 7.69-7.57 (m, 2H), 7.52-7.43 (m, 1H), 7.27-7.08 (m, 4H), 4.02 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 156.78, 148.98, 142.75, 134.77, 131.29, 129.77, 122.10, 121.55, 120.90, 118.46, 118.12, 112.10, 111.97, 55.77 cm⁻¹. IR (KBr pellet) ν 3045, 1603, 1585, 1523, 1489, 1475, 1438, 1394, 1305, 1283, 1247, 1181, 1164, 1091, 1027, 746, 693, 561, 478. Anal. Calcd. for $C_{14}H_{12}N_2O$: C, 74.98; H, 5.39; Found: C, 74.69; H, 5.36.

5-Chloro-2-(2-methoxyphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), an off-white powder was obtained, yield 194 mg (75%, mp 200-201 °C). HNMR (300 MHz, DMSO- d_6) δ 12.30 (s) 12.24 (s) (1H), 8.33 (dd, J = 7.8, 1.8 Hz, 1H), 7.74-7.57 (m, 2H), 7.54-7.45 (m, 1H), 7.24 (d, J = 8.1 Hz, 1H), 7.28-7.17 (m, 1H), 7.12 (td, J = 7.5, 0.6 Hz, 1H), 4.02 (s, 3H). 13 C NMR (75 MHz, DMSO- d_6) δ 156.87, 150.51, 150.17, 143.67, 141.55, 135.49, 133.60, 131.71, 129.84, 126.28, 126.02, 122.23, 121.93, 120.98, 119.72, 117.80, 117.59, 113.29, 112.19, 111.64, 55.85. IR (KBr pellet) v 2958, 1604, 1584, 1480, 1438, 1424, 1390, 1300, 1250, 1250, 1163, 1126, 1096, 1058, 1021, 967, 929, 865, 799, 749, 707, 673, 600, 488, 427, 406 cm⁻¹. Anal. Calcd. for $C_{14}H_{11}$ ClN₂O: C, 65.00; H, 4.29; Found: C, 64.90; H, 4.32.

2-(2-Chlorophenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 60% EtOAc), an off-white solid was obtained, yield 185 mg (81%, mp 217-219 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.76 (s, 1H), 7.95-7.88 (m, 1H), 7.74-7.48 (m, 5H), 7.29-7.20 (m, 2H). ¹³C NMR (75 MHz, DMSO- d_6) δ 149.13, 132.13, 131.66, 131.24, 130.38, 130.00, 127.47. IR (KBr pellet) ν 2772, 1591, 1570, 1491, 1464, 1443, 1405, 1374, 1317, 1275, 1232, 1122, 1054, 1036, 974, 761, 751, 743, 731, 653, 618 cm⁻¹. Anal. Calcd. for C₁₃H₉ClN₂: C, 68.28; H, 3.97; Found: C, 68.22; H, 3.93.

2-(2-(*tert***-Butyldimethylsilyl)phenyl)benzimidazole.** Following the representative procedure, except that the reaction was conducted on a 0.5 mmol scale, after 18 h reaction

time and silica gel chromatography (Hex/EtOAc, gradient 12% to 40% EtOAc), a light brown solid was obtained, yield 124 mg (80%, mp 230-239 °C). 1 H NMR (300 MHz, DMSO- d_6) δ 12.58 (s, 1H), 7.74-7.67 (m, 1H), 7.63 (d, J = 6.6 Hz, 1H), 7.57-7.44 (m, 4H), 7.25-7.13 (m, 2H), 0.90 (s, 9H), -0.08 (s, 6H). 13 C NMR (75 MHz, DMSO- d_6) δ 153.54, 143.28, 138.06, 137.63, 136.31, 134.50, 129.71, 128.54, 128.09, 122.28, 121.35, 118.78, 111.19, 27.73, 17.30, -3.46. IR (KBr pellet) v 2925, 1623, 1549, 1469, 1420, 1368, 1314, 1265, 1215, 1131, 1119, 1069, 1007, 972, 933, 907, 838, 822, 765, 752, 736, 717, 676, 648, 569, 474, 406 cm $^{-1}$. Anal. Calcd. for $C_{19}H_{24}N_2Si$: C, 73.97; H, 7.84; Found: C, 73.87; H, 7.69.

2-(4-Chloro-2-methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 80% EtOAc), a light brown solid was obtained, yield 207 mg (85%, mp 258-260 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.72 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 6.9 Hz, 1H) 7.54 (d, J = 6.9 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.45 (dd, J = 8.4, 2.4 Hz, 1H), 7.29-7.15 (m, 1H), 2.63 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 150.88, 143.69, 139.58, 134.43, 133.83, 131.14, 130.93, 128.94, 126.01, 122.61, 121.60, 119.04, 111.37, 20.93. IR (KBr pellet) v 2663, 1596, 1474, 1451, 1416, 1320, 1273, 1230, 1199, 1108, 968, 874, 820, 767, 750, 574, 456 cm⁻¹. Anal. Calcd. for C₁₄H₁₁ClN₂: C, 69.28; H, 4.57; Found: C, 68.98; H, 4.51.

5-Bromo-2-(4-chloro-2-methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 40% EtOAc), a light yellow foam was obtained, yield 284 mg (88%, mp 165-168 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.90 (s, 1H), 7.80 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.7 Hz, 1H), 7.51-7.47 (m, 1H), 7.44 (dd, J = 8.4, 2.1 Hz, 1H), 7.35 (dd, J = 8.7, 1.8 Hz, 1H), 2.61 (s, 3H). ¹³C (75 MHz, DMSO- d_6) δ 152.10, 139.70, 134.17,

131.19, 130.99, 128.37, 126.06, 124.99, 20.87. IR (KBr pellet) ν 2975, 1599, 1479, 1438, 1407, 1302, 1276, 1200, 1110, 1047, 968, 915, 875, 810, 593, 578, 458, 421 cm⁻¹. Anal. Calcd. for $C_{14}H_{10}BrClN_2$: C, 52.29; H, 3.13; Found: C, 52.07; H, 3.05.

2-(5-Fluoro-2-methylphenyl)benzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 80% EtOAc), an off-white solid was obtained, yield 201 mg (89%, mp 202-203 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.72 (s, 1H), 7.73-7.67 (m, 1H), 7.60 (dd, J = 10.2, 2.7 Hz, 1H), 7.57-7.51 (m, 1H), 7.43 (dd, J = 8.4, 5.7 Hz, 1H), 7.30-7.17 (m, 3H), 2.60 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 161.88, 158.69, 150.76, 150.72, 143.57, 134.41, 133.26, 133.25, 133.20, 133.16, 131.51, 131.41, 122.78, 121.63, 119.16, 116.16, 115.98, 155.88, 115.67, 111.46, 20.49. ¹⁹F NMR (282 MHz, DMSO- d_6) δ -116.79 (q, J = 8.3 Hz). IR (KBr pellet) v 2775, 1589, 1500, 1450, 1421, 1394, 1320, 1267, 1216, 1083, 1014, 989, 870, 818, 753, 743, 468 cm⁻¹. Anal. Calcd. for C₁₄H₁₁FN₂: C, 74.32; H, 4.90; Found: C, 74.11; H, 4.89.

6-Bromo-5-methyl-2-(2-(trifluoromethyl)phenyl)benzimidazole. Following the representative procedure, after 36 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), a white solid was obtained, yield 283 mg (80%, mp 232-234 °C; HPLC: 14:1, GC: 15:1 mixture of regioisomers in favor of the isomer shown; yield corresponds to the mixture of compounds). ¹H NMR (300 MHz, DMSO- d_6) δ 12.88 (s, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.91-7.73 (m, 4H), 7.61 (s, 1H), 2.46 (s, 3H). ¹³C NMR (75 MHz, DMSO- d_6) δ 150.36, 132.47, 132.19, 130.69, 130.42, 129.86, 129.83, 128.07, 127.66, 126.77, 126.72, 126.65, 126.58, 125.52, 121.89, 117.52, 23.02. ¹⁹F NMR (282 MHz, DMSO- d_6) δ -56.51 (s). IR (KBr pellet) v 2954, 1583, 1549, 1438, 1396, 1314,

1269, 1177, 1133, 1056, 1035, 983, 857, 773, 694, 668, 646, 598, 426 cm⁻¹. Anal. Calcd. for $C_{15}H_{10}BrF_3N_2$: C, 50.73; H, 2.84; Found: C, 50.45; H, 2.74.

N-Methyl-2-(2-methylphenyl)benzimidazole. Following the representative procedure, exept that 2.00 eq. HOAc were used instead of 5.00 eq., after 48 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), an off-white solid was obtained, yield 151 mg (68%, mp 118-120 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.88-7.80 (m, 1H), 7.46-7.28 (m, 7H), 3.63 (s, 3H), 2.27 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 153.92, 143.07, 138.15, 135.68, 130.59, 130.42, 130.05, 130.02, 125.91, 122.76, 122.40, 119.99, 109.68, 30.79, 19.86. IR (KBr plate, CDCl₃) v 3053, 1942, 1615, 1526, 1473, 1458, 1430, 1383, 1326, 1278, 1242, 1152, 1133, 1052, 1036, 1005, 931, 828, 783, 755, 733, 669, 599, 555, 463, 442, 414 cm⁻¹. Anal. Calcd. for C₁₅H₁₄N₂: C, 81.05; H, 6.35; Found: C, 81.04; H, 6.37.

N-Methyl-2-(2-chlorophenyl)benzimidazole. Following the representative procedure, exept that 2.00 eq. HOAc were used instead of 5.00 eq., after 48 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), an off-white solid was obtained, yield 167 mg (69%, mp 122-124 °C). ¹H NMR (300 MHz, CDCl₃) δ 7.89-7.81 (m, 1H), 7.62-7.30 (m, 7H), 3.68 (s, 3H), ¹³C NMR (75 MHz, CDCl₃) δ 151.62, 143.01, 135.80, 134.38, 132.59, 131.50, 130.12, 129.86, 127.19, 123.13, 122.54, 120.24, 109.82, 30.98. IR (KBr plate, CDCl₃) ν 3404, 3061, 2946, 2361, 1615, 1602, 1569, 1525, 1456, 1440, 1386, 1328, 1284, 1244, 1152, 1127, 1083, 1037, 1006, 822, 767, 745, 730, 656, 595, 545, 471, 431 cm⁻¹. Anal. Calcd. for C₁₄H₁₁ClN₂: C, 69.28; H, 4.57; Found: C, 69.07; H, 4.51.

N-Methyl-5-bromo-2-(2-chlorophenyl)benzimidazole. Following the representative procedure, exept that 2.00 eq. HOAc were used instead of 5.00 eq., after 48 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 50% EtOAc), a white solid was obtained, yield 269 mg (84%, mp 114-116 °C). 1 H NMR (300 MHz, CDCl₃) δ 7.95 (dd, J = 1.8, 0.6 Hz, 1H), 7.59-7.51 (m, 2H), 7.50 (dd, J = 6.9, 1.8 Hz, 1H), 7.47-7.38 (m, 2H), 7.31-7.25 (m, 2H), 3.65 (s, 3H). 13 C NMR (75 MHz, CDCl₃) δ 152.66, 144.21, 134.78, 134.33, 132.50, 131.80, 129.97, 129.58, 127.32, 126.21, 123.03, 115.59, 111.13, 31.18. IR (KBr plate, CDCl₃) ν 3063, 2947, 1602, 1523, 1469, 1422, 1385, 1319, 1143, 1085, 1044, 912, 866, 839, 795, 767, 750, 733, 660, 593, 567, 433 cm⁻¹. Anal. Calcd. for C₁₄H₁₀BrClN₂: C, 52.29; H, 3.13; Found: C, 52.15; H, 3.02.

N-Methyl-6-bromo-2-(2-chlorophenyl)benzimidazole. Following the representative procedure, exept that 2.00 eq. HOAc were used instead of 5.00 eq., after 48 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 40% EtOAc), a highly viscous yellow oil was obtained, yield 173 mg (54%; HPLC: 5:1, GC: 7.6:1 mixture of regioisomers in favor of the isomer shown; yield corresponds to the isomer shown; minor isomer not isolated in pure form). ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J = 8.7 Hz, 1H), 7.62-7.39 (m, 6H), 3.65 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 152.30, 141.88, 136.87, 134.33, 132.50, 131.79, 129.97, 129.54, 127.32, 125.94, 121.52, 116.40, 113.04, 31.16. IR (KBr plate, CDCl₃) v 3398, 3063, 2946, 1611, 1524, 1466, 1448, 1381, 1327, 1315, 1271, 1237, 1127, 1105, 1083, 1038, 910, 810, 773, 757, 733, 719, 662, 593, 562, 471, 432 cm⁻¹. Anal. Calcd. for C₁₄H₁₀BrClN₂: C, 52.29; H, 3.13; Found: C, 52.21; H, 3.23.

2-*tert*-**Butylbenzimidazole.**^[5] Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 100% EtOAc), a white powder was obtained, yield 150 mg (86%, complete sublimation at 310 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 12.09 (s, 1H), 7.56-7.49 (m, 1H), 7.42-7.37 (m, 1H), 7.16-7.05 (m, 2H), 1.39 (s, 9H). ¹³C NMR (75 MHz, DMSO- d_6) δ 162.15, 142.79, 134.65, 121.44, 120.73, 118.32, 110.77, 33.19, 29.28. IR (KBr pellet) ν 3050, 2965, 2873, 2773, 1621, 1592, 1533, 1486, 1452, 1410, 1362, 1309, 1277, 1222, 1184, 1015, 994, 937, 791, 749, 731, 618, 540, 463, 412 cm⁻¹. Anal. Calcd. for C₁₁H₁₄N₂: C, 75.82; H, 8.10; Found: C, 75.90; H, 8.12.

5-Methyl-2-*tert*-butylbenzimidazole. Following the representative procedure, an off-white solid was obtained after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 70% EtOAc), yield 162 mg (86%, mp 252 °C). H NMR (300 MHz, DMSO- d_6) δ 11.96 (s), 11.94 (s) (1H), 7.39 (d, J = 8.1 Hz), 7.27 (d, J = 8.1 Hz) (1H), 7.32 (s), 7.19 (s) (1H), 6.97-6.87 (m, 1H), 2.39 (s), 2.37 (s) (3H), 1.38 (s, 9H). NMR (75 MHz, DMSO- d_6) δ 162.09, 161.60, 143.19, 140.88, 134.95, 132.68, 130.49, 129.44, 122.72, 122.16, 118.17, 117.89, 110.59, 110.29, 33.17, 33.15, 29.30, 21.36, 21.32. IR (KBr pellet) v 2970, 1633, 1541, 1490, 1456, 1401, 1365, 1309, 1284, 1266, 1233, 1217, 1180, 1000, 861, 805, 761, 737, 603, 417 cm⁻¹. Anal. Calcd. for $C_{12}H_{16}N_2$: C, 76.55; H, 8.57; Found: C, 76.54; H, 8.55.

5-Methoxy-2-*tert***-butylbenzimidazole.** Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 70% EtOAc), an off-white solid was obtained, yield 170 mg (83%, mp 209 °C). ¹H NMR (300 MHz, DMSO- d_6) δ 11.94 (s, 1H), 7.40 (d, J = 8.7 Hz), 7.27 (d, J = 8.7 Hz) (1H), 7.10 (d, J =

1.8 Hz), 6.89 (d, J = 2.1 Hz) (1H), 6.75 (dd, J = 9.3, 2.0 Hz) 6.72 (dd, J = 9.0, 2.1 Hz) (1H), 3.76 (s), 3.74 (s) (3H), 1.37 (s, 9H). ¹³C NMR (75 MHz, DMSO- d_6) δ 162.54, 161.20, 155.30, 154.81, 143.63, 137.19, 135.24, 129.05, 118.70, 110.94, 110.69, 109.73, 101.36, 94.37, 55.42, 55.39, 33.19, 33.14, 29.29. IR (KBr pellet) ν 2968, 2831, 1633, 1598, 1523, 1490, 1455, 1436, 1404, 1365, 1313, 1264, 1219, 1199, 1034, 997, 952, 815, 725, 632, 579, 549, 429 cm⁻¹. Anal. Calcd. for C₁₂H₁₆N₂O: C, 70.56; H, 7.90; Found: C, 70.33; H, 7.87.

5-Bromo-2-*tert*-butylbenzimidazole. Following the representative procedure, after 18 h reaction time and silica gel chromatography (Hex/EtOAc, gradient 12% to 70% EtOAc), a white powder was obtained, yield 229 mg (89%, mp 293 °C). 1 H NMR (300 MHz, DMSO- d_6) δ 12.30 (s, 1H), 7.80-7.32 (m, 2H), 7.25 (dd, J = 8.4, 2.0 Hz, 1H), 1.38 (s, 9H). 13 C NMR (75 MHz, DMSO- d_6) δ 33.28, 29.15. IR (KBr pellet) v 3074, 2970, 1617, 1532, 1478, 1447, 1393, 1364, 1298, 1278, 1243, 1217, 1175, 1052, 996, 915, 864, 807, 739, 682, 595, 414 cm $^{-1}$. Anal. Calcd. for C₁₂H₁₆BrN₂: C, 52.19; H, 5.18; Found: C, 52.26; H, 5.12.

Reactivity Study of Electron-rich and Electron-poor Amidines

To probe the action of an electrophilic aromatic substitution mechanism, we reacted an unsubstituted amidine and amidines substituted with either an electron-donating (OMe) or electron-withdrawing group (CO₂tBu) in the *para* or *meta* position of the aniline-derived part of the amidine. The reactions were stopped after 2, 4, 6, and 8 h and the conversion of the starting material as well as the yield of the formed benzimidazole were assigned based on the GC data (Table 1).

If an electrophilic aromatic substitution mechanism operates, a considerable difference in reactivity should be found for the differently substituted amidines; the highest reactivity should be observed for the amidine with an OMe in the *meta* position, the lowest for the amidine with a CO₂tBu group in the same position. This would be in accordance with the ability of these substituents to stabilize the carbocation in the intermediate of the electrophilic aromatic substitution process (Scheme 1). In our study we observed the highest reactivity for the amidine with an OMe in the *meta* position, the lowest for the amidine with a CO₂tBu group in the same position. This result is consistent in direction, but the difference in reactivity is too small to be certain that an electrophilic aromatic substitution mechanism operates in this transformation.


$$\begin{bmatrix} H & Cu(OAc)_2 & H & R \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ &$$

Scheme 1. Influence of the Substituent and the Substitution Pattern on the Reactivity.


Table 1. Results of the Reactivity Study of Electron-rich and Electron-poor Amidines.


Time	unsubstituted		<i>p</i> -OMe		<i>m</i> -OMe		<i>p</i> -CO ₂ <i>t</i> Bu		<i>m</i> -CO ₂ <i>t</i> Bu Conv. Yield	
	Conv.	Yield	Conv.	Yield	Conv.	Yield	Conv.	Yield	Conv.	Yield
							31%			
4 h	69%	62%	82%	56%	88%	65%	50%	35%	28%	21%
6 h	83%	73%	90%	68%	94%	68%	64%	54%	40%	31%
8 h	87%	80%	94%	70%	96%	71%	74%	63%	46%	41%


Reactions were carried out with 0.5 mmol of the corresponding amidine in 1 mL DMSO. Conversions (Conv.) and yields are based on GC analyses. The data is corrected. Dodecane was used as internal standard.





Spectra














References

- [1] a) B. Singh, J. C. Collins, J. Chem. Soc., Chem. Commun. 1971, 498–499; b) F. C.
 Cooper, M. W. Partridge, J. Chem. Soc. 1953, 255–260.
- [2] a) L.-H. Du, Y.-G. Wang, *Synthesis* **2007**, 675–678; b) G. Speier, L. Párkányi, *J. Org. Chem.* **1986**, *51*, 218–221.
- [3] D. Yang, D. Fokas, J. Li, L. Yu, C. M. Baldino, Synthesis 2005, 47–56.
- [4] R. P. Giani, M. Borsa, E. Parini, G. C. Tonon, Synthesis 1985, 550–552.
- [5] J. Charton, S. Girault-Mizzi, C. Sergheraert, Chem. Pharm. Bull. 2005, 53, 492–497.
- [6] G. A. Russel, L. Wang, R. Rajaratnam, J. Org. Chem. 1996, 61, 8988–8991.